2.12
price down icon0.47%   -0.010
after-market Handel nachbörslich: 2.12
loading

Adagene Inc Adr Aktie (ADAG) Neueste Nachrichten

pulisher
Aug 29, 2025

What data driven models say about Adagene Inc. Depositary Receipt’s futureWeekly Stock Recap & Weekly High Momentum Picks - Newser

Aug 29, 2025
pulisher
Aug 26, 2025

Adagene to Participate in Two Investor Conferences in September - The Manila Times

Aug 26, 2025
pulisher
Aug 26, 2025

Biotech Innovator Adagene Scheduled for Major Wall Street Healthcare Conferences in September 2025 - Stock Titan

Aug 26, 2025
pulisher
Aug 23, 2025

Will Adagene Inc. Depositary Receipt see short term momentumTrade Performance Summary & Smart Swing Trading Techniques - Newser

Aug 23, 2025
pulisher
Aug 21, 2025

Is Adagene (ADAG) Outperforming Other Medical Stocks This Year? - Yahoo Finance

Aug 21, 2025
pulisher
Aug 19, 2025

What moving averages say about Adagene Inc. Depositary ReceiptWeekly Profit Analysis & Daily Chart Pattern Signal Reports - Newser

Aug 19, 2025
pulisher
Aug 17, 2025

HC Wainwright Issues Pessimistic Forecast for Adagene (NASDAQ:ADAG) Stock Price - Defense World

Aug 17, 2025
pulisher
Aug 17, 2025

How to read the order book for Adagene Inc. Depositary Receipt2025 Volatility Report & Weekly High Conviction Trade Ideas - Newser

Aug 17, 2025
pulisher
Aug 16, 2025

Q3 Earnings Forecast for Adagene Issued By Leerink Partnrs - Defense World

Aug 16, 2025
pulisher
Aug 15, 2025

H.C. Wainwright lowers Adagene stock price target to $7 on development path clarity - Investing.com

Aug 15, 2025
pulisher
Aug 14, 2025

Adagene's 22.4% Surge: Clinical Breakthroughs and Strategic Alliances Ignite Biotech Volatility - AInvest

Aug 14, 2025
pulisher
Aug 13, 2025

How institutional ownership impacts Adagene Inc. Depositary Receipt stockPortfolio Gains Report & Risk Controlled Daily Plans - Newser

Aug 13, 2025
pulisher
Aug 13, 2025

What indicators show strength in Adagene Inc. Depositary ReceiptJuly 2025 Gainers & Real-Time Buy Zone Alerts - Newser

Aug 13, 2025
pulisher
Aug 12, 2025

Published on: 2025-08-12 20:31:18 - Newser

Aug 12, 2025
pulisher
Aug 12, 2025

Adagene Reports Six Months 2025 Financial Results and Provides Corporate Updates - GlobeNewswire

Aug 12, 2025
pulisher
Aug 12, 2025

Cancer Drug Breakthrough: Adagene's ADG126 Doubles Standard Survival Rate as Sanofi Backs Development - Stock Titan

Aug 12, 2025
pulisher
Aug 10, 2025

Is Adagene Inc. Depositary Receipt still worth holding after the dipFree Low Risk Picks for Daily Trading - Newser

Aug 10, 2025
pulisher
Aug 10, 2025

Why Adagene Inc. Depositary Receipt is moving todayStock Price Prediction Using AI Tools - Newser

Aug 10, 2025
pulisher
Aug 09, 2025

Q2 Earnings Forecast for Adagene Issued By Leerink Partnrs - Defense World

Aug 09, 2025
pulisher
Aug 08, 2025

Using R and stats models for Adagene Inc. Depositary Receipt forecastingFree AI Forecast for Trending Stocks - Newser

Aug 08, 2025
pulisher
Aug 08, 2025

Adagene (NASDAQ:ADAG) Raised to “Strong-Buy” at Leerink Partnrs - Defense World

Aug 08, 2025
pulisher
Aug 08, 2025

Leerink Partners Begins Coverage on Adagene (NASDAQ:ADAG) - Defense World

Aug 08, 2025
pulisher
Aug 06, 2025

Leerink Partners initiates Adagene stock with Outperform rating on cancer drug potential - Investing.com India

Aug 06, 2025
pulisher
Aug 03, 2025

What are analysts’ price targets for Adagene Inc. Depositary Receipt in the next 12 monthsAccelerated investment success - Jammu Links News

Aug 03, 2025
pulisher
Jul 29, 2025

Why did ADAG's Q4 2020 EPS miss forecasts drastically? - AInvest

Jul 29, 2025
pulisher
Jul 27, 2025

Published on: 2025-07-28 00:29:47 - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 16, 2025

Adagene Receives FDA Approval for Phase 2 Trial of Muzastotug in MSS CRC - AInvest

Jul 16, 2025
pulisher
Jul 16, 2025

Adagene Announces Regulatory Update on Clinical Development - GlobeNewswire

Jul 16, 2025
pulisher
Jul 16, 2025

Adagene (NASDAQ:ADAG) Trading Up 3.8% – Should You Buy? - Defense World

Jul 16, 2025
pulisher
Jul 15, 2025

Adagene Receives FDA Guidance On Future Clinical Development Of Experimental Cancer Drug: Retail Turns Optimistic By Stocktwits - Investing.com India

Jul 15, 2025
pulisher
Jul 15, 2025

Adagene advances muzastotug to phase 2 trial after FDA meeting By Investing.com - Investing.com South Africa

Jul 15, 2025
pulisher
Jul 15, 2025

Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B Meeting with FDA - MarketScreener

Jul 15, 2025
pulisher
Jul 15, 2025

Adagene Advances Clinical Plan for ADG126 in Colorectal Cancer After FDA Meeting - TipRanks

Jul 15, 2025
pulisher
Jul 15, 2025

Adagene advances muzastotug to phase 2 trial after FDA meeting - Investing.com

Jul 15, 2025
pulisher
Jul 15, 2025

Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA - GlobeNewswire

Jul 15, 2025
pulisher
Jul 15, 2025

Adagene's Cancer Drug Shows Breakthrough 29% Response Rate, FDA Fast-Tracks Phase 2 Trial - Stock Titan

Jul 15, 2025
pulisher
Jul 10, 2025

Adagene Inc. and ConjugateBio Inc. Partner to Develop Novel Antibody Drug Conjugate - MarketScreener

Jul 10, 2025
pulisher
Jul 09, 2025

Adagene to provide antibody to ConjugateBio for bispecific ADC development By Investing.com - Investing.com South Africa

Jul 09, 2025
pulisher
Jul 08, 2025

Adagene Partners With ConjugateBio to Develop ADC Programs - MarketScreener

Jul 08, 2025
pulisher
Jul 08, 2025

Adagene and ConjugateBio Partner to Develop Novel Antibody Drug Conjugate - GlobeNewswire

Jul 08, 2025
pulisher
Jul 08, 2025

Adagene to provide antibody to ConjugateBio for bispecific ADC development - Investing.com

Jul 08, 2025
pulisher
Jul 08, 2025

Adagene Enters $30B ADC Market Through Strategic ConjugateBio Partnership for Novel Cancer Therapeutics - Stock Titan

Jul 08, 2025
pulisher
Jul 02, 2025

Adagene Secures $25 Million Investment from Sanofi to Advance Cancer Therapies - TipRanks

Jul 02, 2025
pulisher
Jul 01, 2025

Adagene announces up to $25 million strategic investment from Sanofi - GlobeNewswire

Jul 01, 2025
pulisher
Jul 01, 2025

Sanofi invests up to $25 million in Adagene, exercises third option By Investing.com - Investing.com

Jul 01, 2025
pulisher
Jun 24, 2025

Adagene (NASDAQ:ADAG) Trading 0.3% Higher – Here’s Why - Defense World

Jun 24, 2025
pulisher
Jun 14, 2025

Adagene to present new ADG126 clinical data at ASCO-GI - MSN

Jun 14, 2025
pulisher
Jun 03, 2025

Is McKesson (MCK) Outperforming Other Medical Stocks This Year? - Yahoo Finance

Jun 03, 2025
pulisher
Jun 02, 2025

Adagene Announces Participation At Leerink’s Global Healthcare Conference 2025 - Bernama

Jun 02, 2025
pulisher
May 31, 2025

Adagene Inc. (NASDAQ:ADAG) Sees Significant Growth in Short Interest - Defense World

May 31, 2025
pulisher
May 27, 2025

Adagene to Present at Jefferies Global Healthcare Conference 2025 - The Manila Times

May 27, 2025
pulisher
May 27, 2025

Adagene Inc. to Participate in Jefferies Global Healthcare Conference 2025 with Fireside Chat and Investor Meetings - Nasdaq

May 27, 2025
pulisher
May 27, 2025

Exclusive: Adagene Leadership Reveals Latest Antibody Therapeutic Strategy at Major Jefferies Conference - Stock Titan

May 27, 2025
pulisher
May 23, 2025

Adagene (NASDAQ:ADAG) Trading Down 2.1% – Here’s Why - Defense World

May 23, 2025
pulisher
May 22, 2025

Adagene Reports Promising ADG126 Study Results at ASCO - TipRanks

May 22, 2025
pulisher
May 22, 2025

Adagene Announces Updated Data from Phase 1b/2 Study of - GlobeNewswire

May 22, 2025
pulisher
May 22, 2025

New Clinical Data: Adagene's ADG126 Achieves Breakthrough 29% Response Rate in Hard-to-Treat Colorectal Cancer - Stock Titan

May 22, 2025
pulisher
May 13, 2025

ADAGAdagene Inc. Latest Stock News & Market Updates - Stock Titan

May 13, 2025
pulisher
Apr 30, 2025

Adagene Inc. (NASDAQ:ADAG) Short Interest Update - Defense World

Apr 30, 2025
$25.89
price up icon 4.10%
$85.98
price up icon 1.62%
$23.84
price up icon 0.59%
$100.62
price up icon 0.62%
$145.30
price up icon 6.76%
biotechnology ONC
$332.04
price up icon 8.49%
Kapitalisierung:     |  Volumen (24h):